Authors


Loreen M. Brown

Latest:

Patient Adherence: Balancing High-Tech with High-Touch

Loreen M. Brown discusses how technology has influenced how healthcare teams function, from leveraging and delivering care to interacting with patients throughout the patient journey.


Mike Rutstein

Latest:

"There's a Cure for That..."

Cures and therapies with curative intent are here in hepatitis C and are coming in other serious diseases. So everyone, from pharma suppliers patients, is scrambling to figure out what this means, writes Mike Rutstein.





David Hole

Latest:

Taking Flight: Pharm Exec's Top 50 Pharma Companies 2015

 Specialty drug sales, record-breaking M&A paired with tax synergies, and global expansion helped to bring a new face into this year’s Pharma 50 top 10, and substantially boosted the rankings of several others.    


Kim White

Latest:

When Care Models Collide

What you should know about integrated delivery networks.


Christen Buseman

Latest:

When Care Models Collide

What you should know about integrated delivery networks.



Sponsored Content

Latest:

Optimizing Clinical Trials Using Electronic Measurement and Analysis of Drug Adherence

Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority


Gregg Metzger

Latest:

Sales Personnel Contracts, Sword or Shield for M&A Valuation

Determining a company’s acquisition/merger value requires an intensive due diligence process. Attorney Gregg Metzger discusses salesforce contracts which, especially for life science companies, cannot be overlooked.




Mikkel Brok-Kristensen

Latest:

Towards Real-World Patient Centricity

Patient centricity requires clinical trials to be based on life outside the lab, writes Mads Holme.


Roger Humphrey

Latest:

Give Them Their Space

To attract the best talent, offer a workplace that inspires.


Victoria Allan

Latest:

Why Is It Such a Challenge to Treat PAH?

Despite recent advances, there continue to be significant issues that compromise the effective management of pulmonary arterial hypertension, writes Victoria Allan.


Pharmaceutical Executive Editorial Staff

Latest:

Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches

Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.



Sarah Chaney

Latest:

The Salix-Valeant Acquisition: "It’s Just a Game"

Sarah Chaney gives an in-depth look at the Salix-Valeant acquisition - how analysts and investors can affect decision-making and potentially drive poor behavior.


WestRock

Latest:

Patient-centric innovation in packaging moves beyond regulatory requirements to deliver brand differentiation and increased sales

Not so long ago, pharmaceutical brand managers considered drug packaging an afterthought. Today, packaging not only matters, it is quickly becoming one of the most important considerations in the growth and success of any drug product. Manufacturers now consider innovative, smart packaging that pleases patients in their new roles as consumers, and encourages brand loyalty to be a game changer in an increasingly competitive and crowded biopharmaceutical market.


Sophie Daniel

Latest:

Europe Needs News Timeline for IDMP Implementation

All indications are that the July 2016 deadline for transition from Europe's eXtended EudraVigilance Medicinal Product Dictionary (XEVMPD) to the new Identification of Medicinal Products (IDMP) is not achievable. Sophie Daniels reports.


Kathleen Iacocca, Yao Zhao

Latest:

Resell vs. Direct Models: US Branded Drug Distribution in the Future

Kathleen Iacocca and Yao Zhao discuss why direct supply chain models can be more sustainable than resell models in the long run and whether they can be implemented in the US.



Stacie Heller

Latest:

New Payment Models: It's Time to Move

Commercial success for pharma brands now demands proactive strategies and interventions


Peter Weissberg

Latest:

New Payment Models: It's Time to Move

Commercial success for pharma brands now demands proactive strategies and interventions




Mara Senn

Latest:

Stop Everything! Investigating FCPA Issues in Pharma

An internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice.


Rik van Mol

Latest:

How eTMFs Are Transforming the Pharma Industry

A significant change is under way as the industry shifts from passive to active trial master file (TMF) management, writes Rik van Mol.